You are here

A Pilot Clinical Study to Evaluate Liraglutide-Mediated Anti-Platelet Activity in patients with Type 2 Diabetes (ELAID)

Background: A novel class of agents, the Glucagon-like Peptide-1 Receptor (GLP-1R) agonists have recently been introduced to treat type 2 diabetes. Large scale cardiovascular safety studies suggests one member of this class of agents, liraglutide, may have additional cardioprotective effects although the mechanisms responsible for these effects are currently unknown. Receptors for GLP-1 agonists have recently been identified on human platelets with GLP-1R agonists able to inhibit platelet aggregation offering one potential mechanism for improvement in cardiovascular outcomes in patients treated with these agents. Project: A pilot clinical trial is being established to evaluate the effects of liraglutide treatment on platelet aggregation and function in patients with type 2 diabetes. The trial will run over 6 months and recruit 40 patients (20 placebo and 20 treated. The project will enable the successful candidate to become involved in all aspects of clinical trial organisation from patient recruitment to sample and data collection and management together with result analysis, presentation and manuscript production. A laboratory component to the project will include participation in specialised platelet function testing which will be undertaken at the Australian Centre for Blood Diseases located at the Alfred Hospital AMREP facility. Computer literacy and statistical methodology training together with basic medical laboratory experience would be an advantage.
Essential criteria: 
Minimum entry requirements can be found here:
Clinical trial, Type 2 Diabetes, GLP-1 Receptor agonists
Eastern Health Clinical School
Available options 
Time commitment 
Physical location 
Eastern Health Clinical School and ACBD, AMREP Facility (<10%)

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.